Comparison · NCT04550936-4eec0a48
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Isavuconazole Administered as Part of Combination Therapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Invasive Aspergillosis vs Mucormycosis: Number of Participants With Isavuconazole Administered as Part of Combination Therapy. Trial comparisons, record NCT04550936-4eec0a48. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04550936-4eec0a48
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.209 | 0.163 | 0.263 | wilson | |
| Risk in group 2 | 0.614 | 0.466 | 0.743 | wilson | |
| Risk difference, group 1 minus group 2 | -0.405 | -0.542 | -0.248 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.34 | 0.243 | 0.475 | log | |
| Odds ratio, group 1 over group 2 | 0.166 | 0.0843 | 0.327 | log | |
| Number needed to treat, for one fewer participant with the outcome on Invasive Aspergillosis than on Mucormycosis | 2.47 | 1.85 | 4.03 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Invasive Aspergillosis | Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group. | 53 | 254 | OG000 |
| Group 2 | Mucormycosis | Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group. | 27 | 44 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Isavuconazole Administered as Part of Combination Therapy
- Description
Number of participants with index treatment administered as part of antifungal combination therapy were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019. one participant could have received more than one treatment
- Time frame
From index date until 6 months after post-index treatment discontinuation, death, or loss to follow-up, whichever occurred first (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
- Population
Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
- NCT number
- NCT04550936
- Phases
- Conditions
- Invasive Aspergillosis, Mucormycosis
- Interventions
- Isavuconazole
- Lead sponsor
- Pfizer
- Results first posted
- 2025-12-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04550936?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04550936-4eec0a48